Drug Trial Radar · NCT04153149
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
655
Actual
Start
Nov 26, 2019
Primary completion
May 8, 2024
Study completion Jan 13, 2027
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Nov 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
VutrisiranDrug
Vutrisiran will be administered by SC injection.
Sterile Normal Saline (0.9% NaCl)Drug
Sterile normal saline (0.9% NaCl) will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall PopulationTime frame: Up to Month 36
- Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy SubgroupTime frame: Up to Month 36
Locations
121 sites in 33 countries. Site status is shown where the registry gives one.
Clinical Trial Site
La Mesa, California
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Stanford, California
Clinical Trial Site
Washington D.C., District of Columbia
Clinical Trial Site
Gainesville, Georgia
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Evanston, Illinois
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
Manhasset, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Durham, North Carolina
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Allentown, Pennsylvania
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Houston, Texas
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Adelaide, Australia
Clinical Trial Site
Darlinghurst, Australia
Clinical Trial Site
Melbourne, Australia
Clinical Trial Site
Northmead, Australia
Clinical Trial Site
Woolloongabba, Australia
Clinical Trial Site
Graz, Austria
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Brussels, Belgium
Clinical Trial Site
Dendermonde, Belgium
Clinical Trial Site
Ghent, Belgium
Clinical Trial Site
Leuven, Belgium
Clinical Trial Site
Québec, Canada
Clinical Trial Site
Toronto, Canada
Clinical Trial Site
Bogotá D.C., Colombia
Clinical Trial Site
Zagreb, Croatia
Clinical Trial Site
Olomouc, Czechia
Clinical Trial Site
Prague, Czechia
Clinical Trial Site
Aarhus N, Denmark
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.